A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Inavolisib (Primary) ; Letrozole; Palbociclib
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms INAVO123
- Sponsors Roche
- 31 Jan 2025 New trial record